by James Smith | Jan 26, 2015
With contributions from David Brindley . Cell-based treatments are being developed and marketed for a variety of indications: from rare orphan diseases like graft versus host disease (GvHD), to blockbuster conditions like diabetes and cardiovascular disease that...
by Mark Curtis | Jan 7, 2015
. Welcome to your deal review for the month of December. Juno Therapeutics made its leap into the public realm with the largest biotech initial public offering (IPO) in 2014. bluebird Bio announced pricing of a common offering to raise over $200M. Read on to find out...
by Mark Curtis | Dec 23, 2014
. Welcome to your Update from the Clinic for the month of November. NeoStem announced initial positive data from its Phase 2 study in acute myocardial infarction. Neuralstem’s human neural stem cells are shown to have long-term viability following transplant, while...
by James Smith | Dec 18, 2014
. With contributions from David Brindley Manufacturing may not be the first thing that springs to mind when regenerative medicine is mentioned. Most will think of the enormous potential for cell therapies or transplantation or editing of faulty genes. However, having...
by James Smith | Dec 11, 2014
. With contributions from David Brindley. We recently discussed the role that consortia could play in accelerating the timeline of discovering and implementing new treatments, covering the ‘partnering’ aspect of the ‘Partnering for Cures’ conference held in New York...
Comments